1 |
Recombinant antibody fragments to vascular associated targets of human tumoursRubins, Leigh Ruth January 2001 (has links)
No description available.
|
2 |
Untersuchungen zur VEGF und PlGF induzierten Chemotaxis multipotenter Stromazellen des KnochenmarksLeucht, Frank Martin. January 2008 (has links)
Ulm, Univ., Diss., 2008.
|
3 |
In-vitro-VEGF-Sekretion von malignen Schilddrüsenzelllinien Einfluss von Wachstumsfaktoren und Untersuchung der Postrezeptorsignaltransduktion /Geyer, Vera Carina. Unknown Date (has links) (PDF)
Marburg, Universiẗat, Diss., 2008.
|
4 |
Die Bedeutung des Vaskular-Endothelialen Wachstumsfaktor (VEGF) in der Heilung von Frakturen unter Weichteilschaden und SchockJehle, Mirjam. January 2006 (has links)
Ulm, Univ. Diss., 2006.
|
5 |
Role of RNA Processing Factors in the Expression of Flt-1 and its Secreted Variant, sFlt-1Roche, Rebecca I. 21 November 2005 (has links)
Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen involved in angiogenesis, the formation of new blood vessels. sFlt-1, a secreted form of the signal-transducing VEGF receptor Flt-1, can inhibit cellular responses to VEGF both in vitro and in vivo. sFlt-1 is generated by alternative pre-mRNA processing; removal of Flt-1 intron 13 by splicing produces the mRNA for transmembrane Flt-1, whereas cleavage/polyadenylation within this intron, preserving the exon 13/intron 13 junction, yields sFlt-1 mRNA. Despite the likely importance of sFlt-1 in VEGF signaling, little is known about the regulation of its expression.
Previous studies using an Flt-1 minigene (pFIN13) revealed that intronic cleavage/polyadenylation signals can affect Flt-1 expression, and, conversely, that 3' intronic splice signals can affect sFlt-1 expression. The goal of present work was to test the hypothesis that splicing and cleavage/polyadenylation factors compete functionally on Flt-1 transcripts, by 1) assessing the influence of exon 13/14 splicing determinants on expression of Flt-1 RNA processing variants in a transfected cell model system; 2) determining the effects of altering the relative abundance of proteins principally involved in splicing or cleavage/polyadenylation; and 3) characterizing a previously-unknown splice variant, predicted to encode a novel sFlt-1 protein isoform, in cells overexpressing the spliceosomal RNA binding protein U2AF65.
When the upstream exon in pFIN13 was decreased from 2135 to 309 bp, the sFlt-1:Flt-1 mRNA ratio decreased 8.9-fold and an aberrant 5'UTR/exon 14 splice decreased 60-fold, indicating that "exon definition" is a key parameter of successful Flt-1 RNA processing. Mutation of 5' or 3' intronic splice signals had little effect on Long sFlt-1:Total sFlt-1 mRNA ratio, suggesting that splicing and cleavage/polyadenylation factors may not compete physically for Flt-1 transcripts. Although co-transfection with RNA processing factor cDNAs did not generally produce the predicted pattern of effects on sFlt-1:Flt-1 mRNA ratio, a cryptic exon within intron 13 was revealed in cells overexpressing U2AF65. sFlt-1 protein apparently can be encoded by mRNAs either cleaved/polyadenylated within intron 13 or, surprisingly, by splicing of the cryptic exon "13b." Thus, the cellular decision to produce sFlt-1 or Flt-1 from a nascent RNA can no longer be viewed as a simple choice between cleavage/polyadenylation and splicing. / Ph. D.
|
6 |
Autocrine activity of vascular endothelial growth factor (VEGF) in hematological malignanciesKuo, Ching-Yuan 09 September 2004 (has links)
Angiogenesis is not only essential for tumor growth but is also implicated in invasion of the cancer cells into the circulation, and growth of dormant micro-metastases into frank metastatic lesions. Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis as well as in solid tumors. It also has a role for VEGF in hematopoietic neoplasms; although has not been fully elucidated. This study will examine the VEGF secretary activity of malignant cells in the patients with hematologic malignancies. Supernatants of cell culture after 72 hours & 7th day were analyzed for VEGF value by ELISA method. The purposes of this study are to assay the VEGF activity and its correlation with disease prognosis in various hematological disorders; and to detect the VEGF autocrine activity of tumor cells in sequential culture without any stimulation in vitro.
Results: our research samples were 75 specimens. The VEGF value was low in 13 cases of benign diseases, no obvious auto-secretary activity of those cells. There was no significant correlation between VEGF value and disease status in acute lymphoblastic leukemia; however, the cases were too small to had exact predict value (only 7 cases). In 17 Cases of malignant lymphoma, low D0 VEGF value (<300 pg) had good prognosis; those cases relapsed after treatment had high auto-secretary activity (high VEGF value of 7th culture day) and had bad disease prognosis, but there was no statistic significance. In 14 Cases of acute myelogenous leukemia, high D0 VEGF value (>150 pg) and high VEGF value of 7th culture day both presented bad disease outcome. In 16 cases of chronic myeloid leukemia (CML), low plasma VEGF level (D0<300pg) was all in chronic phase; all cases in accelerated phase (3 cases) and acute blastic crisis (5 cases) presented with high plasma VEGF level (>300pg). Patients with high plasma VEGF level had 70 % (7of 10) in worse disease status (P=0.010). Patients in chronic phase of CML had low VEGF auto-secretary activity and most of the blastic crisis patients were with high VEGF auto-secretary activity and also had bad prognosis. (P=0.248)
Conclusion: although our study is a primary result, study cases are varied, but it still provide important information that VEGF has an important role in hematological malignancies. We will process further research of single and specific disease in the future to analyze the exact correlation of VEGF and hematological diseases.
|
7 |
Vascular Endothelial Growth Factor als Risikofaktor für Motoneuronerkrankungen - eine Analyse von Genotyp und PhänotypRehbein, Inga Kristina, January 2008 (has links)
Ulm, Univ., Diss., 2008.
|
8 |
Untersuchung der Funktion des angiogenen Faktors VEGF in der Entwicklung des zentralen Nervensystems /Raab, Sabine. January 2001 (has links)
Universiẗat, Diss--Gießen, 2001.
|
9 |
Vaskulärer endothelialer Wachstumsfaktor-A aktiviert kalziumaktivierte Kalium-Kanäle in humanen Venenendothelzellen in vitroRaithel, Jochen Bernhard. January 2001 (has links)
Ulm, Univ., Diss., 2001.
|
10 |
Der vaskuläre endotheliale Wachstumsfaktor VEGF hemmt die Endothelzellapoptose über Regulation von PARPHörmann, Mareike. Unknown Date (has links)
Univ., Diss., 2010--Marburg.
|
Page generated in 0.085 seconds